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Abstract
Purpose The purpose of this paper was to review the available approaches for bone strength assessment, osteoporosis diag-
nosis and fracture risk prediction, and to provide insights into radiofrequency echographic multi spectrometry (REMS), a 
non-ionizing axial skeleton technique.
Methods A working group convened by the European Society for Clinical and Economic Aspects of Osteoporosis and 
Osteoarthritis met to review the current image-based methods for bone strength assessment and fracture risk estimation, and 
to discuss the clinical perspectives of REMS.
Results Areal bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DXA) is the consolidated 
indicator for osteoporosis diagnosis and fracture risk assessment. A more reliable fracture risk estimation would actually 
require an improved assessment of bone strength, integrating also bone quality information. Several different approaches 
have been proposed, including additional DXA-based parameters, quantitative computed tomography, and quantitative 
ultrasound. Although each of them showed a somewhat improved clinical performance, none satisfied all the requirements 
for a widespread routine employment, which was typically hindered by unclear clinical usefulness, radiation doses, limited 
accessibility, or inapplicability to spine and hip, therefore leaving several clinical needs still unmet. REMS is a clinically 
available technology for osteoporosis diagnosis and fracture risk assessment through the estimation of BMD on the axial 
skeleton reference sites. Its automatic processing of unfiltered ultrasound signals provides accurate BMD values in view of 
fracture risk assessment.
Conclusions New approaches for improved bone strength and fracture risk estimations are needed for a better management 
of osteoporotic patients. In this context, REMS represents a valuable approach for osteoporosis diagnosis and fracture risk 
prediction.
Keywords Bone strength assessment · Osteoporosis diagnosis · Fracture risk · REMS · Ultrasound · Lumbar spine · 
Femoral neck
Introduction
Osteoporosis is a systemic skeletal disease characterised by 
the reduction in bone mass and the degeneration of bone 
structure that leads to an increased risk of fracture [1], with 
important social, medical and community care costs.
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Bone strength, which is a measure of the resistance to 
bone fracture [2], is determined by a composite summation 
of numerous skeletal characteristics that can be divided 
into four basic components: composition, microarchitec-
ture, size, and shape (Fig. 1). Several factors contribute 
to the definition of each skeletal characteristic, such as 
cellular density, mineralization, collagen crosslinking at 
a nanoscale level for the definition of bone composition; 
trabecular and cortical properties including porosity, thick-
ness, connectivity at microscale level for the definition of 
bone microarchitecture; age, genetics, gender, and habits 
for the definition of bone size and shape at a macroscale 
level. Understanding how these variables interact and con-
tribute to bone strength is critical in the development of 
fracture prediction tools [3, 4].
Available imaging techniques are able to capture a 
measure of the aforementioned factors and could also 
provide information about bone strength. Therefore, in 
principle, several tools are necessary to assess the differ-
ent bone properties, such as spectroscopy and microscopy 
at nano-scale level, high-resolution quantitative computed 
tomography (HR-QCT) or µCT at micro-scale level, dual-
energy X-ray absorptiometry (DXA) or CT at macro-scale 
level [3, 4]. Nowadays, in clinical practice, bone strength 
is indirectly estimated by bone mineral density (BMD) 
measured by DXA, which currently represents a well-
recognized technology for the diagnosis of osteoporosis 
worldwide. Nonetheless, several studies demonstrated that 
BMD only accounts for about 50–70% of the bone strength 
variation, being able to describe features related to the 
quantity of bone tissue but overlooking information about 
bone quality [4–6].
These considerations argue for the introduction in clinical 
routine of further tools in order to better define and estimate 
bone strength and to predict the risk of fracture.
To address this, a working group convened by the Euro-
pean Society of Clinical and Economic Aspects of Oste-
oporosis and Osteoarthritis (ESCEO) met to review the 
data on the currently available imaging techniques for the 
in vivo bone strength assessment and to discuss principles, 
applications and perspectives of a new technology called 
Radiofrequency Echographic Multi-Spectrometry (REMS) 
on the basis of the latest available data. Specific attention 
has been paid to identify the clinical needs related to bone 
strength assessment, fracture risk prediction and osteoporo-
tic patient management that are not completely satisfied by 
the techniques currently employed in clinical routine and to 
their possible resolution by the introduction of innovative 
approaches.
Clinical assessment of bone strength
Several approaches have been developed to provide an esti-
mation of bone strength, including imaging devices, risk 
fracture calculators, bone biopsy techniques, and laboratory 
tests (Table 1). In this review, we will focus on the imaging 
devices: the main features of the most common approaches 
are described and discussed in the following paragraphs.
Dual‑energy X‑ray absorptiometry
The most widely used technique to obtain information about 
bone strength is DXA, currently considered as the gold 
Fig. 1  Factors contributing to bone strength. The ultimate definition of bone strength is complex, but four main categories of bone characteristics 
that contribute to bone strength can be outlined at different scale level: size, shape, architecture and composition [3]
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standard densitometric technique for the diagnosis of osteo-
porosis. Through the acquisition of two-dimensional (2D) 
X-ray scans with an effective dose in the range of 1–13 µSv 
[7–9], it estimates an areal BMD expressed in g/cm2 (i.e., 
the ratio between bone mineral content estimated through 
X-ray absorption and 2D projection of the scanned bone 
area), which is a surrogate measure of bone strength [3]. 
Ex vivo studies performed on isolated human bones showed 
that areal BMD accounts for about two thirds of the variation 
of bone strength as evaluated by shear test of the femoral 
neck or compression of the vertebrae [5, 10].
In clinical practice, DXA is employed to categorise the 
patient by comparing the measured BMD value with the 
average BMD of a reference healthy population of young 
individuals, which allows to define the patient’s T-score 
as the number of standard deviations (SDs); the measured 
BMD differs from the reference value. Thus, patients are 
classified as healthy (normal BMD, T-score ≥ − 1), osteo-
penic (− 2.5 < T-score < − 1), osteoporotic (T-score ≤ − 2.5) 
or severely osteoporotic (T-score ≤ − 2.5 in the presence of 
one or more fragility fractures), according to the definitions 
given by the World Health Organization (WHO) [11, 12]. 
Moreover, DXA is employed to provide prognostic informa-
tion on probability of fracture and to monitor bone status 
in longitudinal studies [13]. A meta-analysis of prospective 
cohort studies correlating the baseline BMD with the subse-
quent follow-up for fractures showed that the measurement 
at the spine and at the hip seemed to have a better predictive 
ability for spine and hip fractures, respectively [14]. Les-
lie et al. investigating whether the rate of BMD loss would 
predict fracture risk independently of current BMD, found 
that routine clinical DXA measurement in untreated women 
cannot accurately characterise the rate of BMD loss due to 
the dominating effect of measurement errors [15].
BMD alone for the assessment of fracture risk has a high 
specificity but low sensitivity, with many fragility frac-
tures occurring in patients who did not have a diagnosis for 
osteoporosis as defined by the WHO classification based on 
T-score value, but whose BMD lay in the osteopenic range 
[16–18]. Moreover, in the diabetes paradigm, BMD is unable 
to explain the increased risk of fracture: in particular, for 
Type 1 diabetes, the highly increased risk of hip fracture was 
only partially explained by the observed BMD reduction, 
whereas in Type 2 diabetes the increased risk of fracture is 
not captured by the paradoxically higher BMD [19].
Thus, a screening program for osteoporosis based on 
DXA-measured BMD alone cannot be recommended for 
the whole population [20, 21], and further studies evaluat-
ing the most cost-effective screening strategy are warranted 
[22]. These findings also suggest the hypothesis that multi-
ple factors, other than BMD, contribute to fracture risk and 
highlight the importance of BMD-independent determinants 
of bone strength and fracture risk assessment.
DXA scanners, if equipped with dedicated software 
modules, can also measure additional parameters related to 
textural features and hip geometry, as described in the sub-
sequent paragraphs.
Trabecular bone score
The Trabecular Bone Score (TBS), calculated by the soft-
ware package TBS  iNsight® (Medimaps Group SA, Geneva, 
Switzerland), is a unit-less indirect index of trabecular 
microarchitecture based on pixel grey level variations in the 
DXA images [23, 24]. The large clinical database of the 
Province of Manitoba (Canada), including 29,407 women 
aged over 50 years at baseline, has been used for several 
investigations aimed at assessing the ability of TBS in frac-
ture risk prediction. Although TBS (along with BMD and 
additional clinical risk factors) helps to identify individuals 
at high risk of fracture and to guide initiation of osteoporosis 
treatment [25], change in lumbar spine TBS is not a useful 
indicator of fracture risk regardless of osteoporosis treatment 
[26]. Another retrospective study on the Manitoba database 
showed the ability of lumbar spine TBS to predict osteoporo-
tic fractures in patients with type 2 diabetes, whereas BMD 
was paradoxically increased in these patients [27].
TBS values can be also input into the Fracture Risk 
Assessment tool  FRAX® [28]. This tool, available online 
at www.shef.ac.uk/FRAX [29], aims to predict osteoporo-
tic fractures on the basis of several risk factors optionally 
including femoral neck BMD or spinal TBS [17]. A recent 
meta-analysis showed that TBS, adjusted for time since 
Table 1  Main currently available tools for the in vivo assessment of 
bone strength
Category Tool
Imaging devices Dual X-ray absorptiometry (DXA)
Quantitative CT (QCT)
High resolution peripheral QCT (HR-
pQCT)
Magnetic resonance imaging (MRI)
Quantitative ultrasound (QUS)
Radiofrequency echographic multi spec-
trometry (REMS)
Risk fracture calculators FRAX®
Qfracture®
Garvan®
DVO risk  calculator®
Bone biopsy techniques Static histomorphometry
Dynamic histomorphometry
Laboratory tests Bone turnover markers (BTMs)
Single nucleotide polymorphisms (SNPs)
Micro-ribonucleic acid (miRNA)
Others Microindentation
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baseline measurement and age, has a significant correlation 
with major osteoporotic fractures, which is slightly improved 
when  FRAX® probability is taken into account, supporting 
the use of TBS both as a stand-alone fracture risk prediction 
tool and as a valuable add-on to  FRAX® [30].
Nonetheless, some limitations of TBS should be also 
mentioned: increased noise in DXA images results in an 
artefactually reduced TBS [31]; TBS, but not BMD, is 
dependent on the used scan mode (standard versus thick), 
at least for GE Lunar Prodigy scanners [32]; increases in 
soft-tissue thickness overlying the spine lead to diminished 
TBS [33]; TBS reliability in men depends on BMI [34, 35].
Furthermore, a debate is still open in the scientific lit-
erature as regards the proportion in which TBS explains the 
variability in vertebral strength. The very few available bio-
mechanical studies [36, 37], which anyway represent only 
an indirect approach to what happens in vivo, found poor 
or no direct correlation between TBS and vertebral failure 
load, although reporting in some cases significant correla-
tions with other elastic properties (e.g., r = 0.64 with bone 
stiffness [36]).
Overall, lumbar spine TBS is an evolving software that 
has been shown to be useful as a complementary frac-
ture risk prediction tool. However, the magnitude of TBS 
increase in osteoporosis treatment is smaller than that of 
BMD. The relationship between change in TBS and frac-
ture risk reduction remains to be elucidated with recent and 
ongoing studies that are helping to refine its clinical utility 
[28, 38].
Hip axis length and hip structural analysis
The hip axis length (HAL), i.e. the distance from the base 
of the greater trochanter to the inner pelvic rim (Fig. 2), is a 
further non-BMD parameter that has been considered for the 
assessment of hip bone strength through DXA [39]. A study 
by Leslie et al. [40] showed that the risk of hip fracture, 
adjusted for age and femoral neck BMD, increases by 3.6% 
in men (p = 0.022) and by 4.6% in women (p < 0.001) for 
every millimetre of increase in HAL. However, as pointed 
out by the International Society of Clinical Densitometry 
(ISCD) at the 2015 Position Development Conference, 
the association between HAL and hip fracture is actually 
ambiguous, with 14 published studies showing a positive 
association between HAL and hip fracture, 11 studies show-
ing no association and 1 study reporting a negative associa-
tion [41]. On this basis, the Hip Structural Analysis (HSA) 
software was developed to simultaneously evaluate both hip 
geometrical information and corresponding mineral mass 
data derived from DXA images [42]. Whether HSA could 
be actually useful for clinical assessment of bone fragility is 
currently under investigation, with few studies showing that 
some factors, i.e. cortical thickness of the intertrochanteric 
region [43], HAL and neck shaft angle [44] might have a 
role in fracture risk assessment for specific categories of 
patients.
Quantitative computed tomography
Quantitative computed tomography (QCT) allows to obtain a 
tomographic 3D reconstruction of the scanned bone and pro-
vides a volumetric bone mineral density (vBMD), expressed 
in g/cm3, which is less susceptible to osteo-arthritis artefacts 
than the areal BMD measured by DXA. Depending on the 
specific adopted protocol, the exposure dose for a lumbar 
QCT scan is in the range of 50–500 µSv, which is clearly 
lower than a standard abdominal CT scan (approximatively 
8 mSv) [7, 8]. In contrast to DXA, this analysis allows sepa-
rate estimation of trabecular and cortical BMD. Since tra-
becular bone has a substantially higher metabolic turnover 
than cortical bone, QCT is more sensitive to changes in 
BMD than DXA [45]. The American College of Radiology 
(ACR) has recently introduced practice guidelines for the 
use of QCT, with the definition of equivalent WHO clas-
sification of osteoporosis classes based on spine trabecular 
volumetric BMD measurements and an association between 
volumetric BMD and risk of fracture has also been estab-
lished. Moreover, the correlation between BMD measured 
by QCT and derived by DXA has also been assessed. Thus, 
QCT might be used in case of non-availability of DXA. It 
Fig. 2  Representation of the Hip Axis Length (HAL) definition, i.e. 
the distance from the base of the greater trochanter to the inner pelvic 
brim (segment a–b). Angle c is the neck shaft angle, i.e. the angle 
between the derived axes of the femoral neck and shaft
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has also some important advantages over DXA that are use-
ful in specific clinical indications, i.e. abnormal body size 
(small/large body frame) or very obese patients, advanced 
degenerative spine disease (e.g. idiopathic skeletal hyperos-
tosis, degenerative disc disease, facet arthropathy), and need 
for accurate monitoring of trabecular metabolic activity [46].
In addition, QCT allows the development of finite-ele-
ment analysis (FEA), a computational method in which 
each voxel represents a finite element with assigned material 
properties (e.g., elastic modulus). Load simulations might 
be performed with the estimation of the load at which struc-
tural failure occurs, so identifying a biomechanical fracture 
threshold [47]. Indeed, the prospective 5-year AGES-Reykja-
vik case–control study of 1110 patients reported significant 
correlation between bone strength estimated by FEA and 
fracture occurrence, with age-adjusted odds ratios for low 
vertebral strength and incident spine fractures of 2.8 (95% 
CI 1.8–4.3) and 2.2 (2.2, 95% CI 1.5–3.2), and age-adjusted 
odds ratios for low femoral strength and incident hip frac-
tures of 4.2 (95% CI 2.6–6.9) and 3.5 (95% CI 2.3–5.3) for 
women and men, respectively [48]. The FEA performed on 
QCT images also provides information on femoral strength 
changes associated with therapies, as in the “PaTH” study 
evaluating the effects of PTH(1–84) and/or alendronate in 
osteoporotic women [49]. It was shown that strength was 
mainly influenced by trabecular density changes, regardless 
of the pharmacological treatment, although changes in the 
cortical bone density and overall bone geometry also con-
tributed to femoral strength changes, in that case depending 
on the drug used. Due to the limited clinical availability of 
QCT and to the associated high costs and radiation doses 
[50], in the past years, several studies investigated the pos-
sibility to obtain finite-element models from DXA imaging, 
but their clinical feasibility remains very limited and their 
actual usefulness should be further explored [51–53].
Peripheral QCT (pQCT) has a more widespread avail-
ability and examines appendicular skeleton sites with a 
lower effective radiation dose than central QCT (lower than 
0.01 mSv [8]). Through the simultaneous calculation of 
BMD, bone and muscle geometrical parameters, and bio-
mechanical parameters, it provides an evaluation of the 
“muscle-bone unit”, with the potential of representing a 
valid functional approach for bone health assessment [54]. 
However, with respect to DXA, pQCT has anyway a more 
limited accessibility, being also sensitive to motion artefacts.
High‑resolution peripheral QCT
High-resolution peripheral QCT (HR-pQCT), with a sin-
gle scan exposure dose of about 3–4 µSv [55, 56], allows 
one to obtain volumetric images of distal bones, i.e. radius 
and tibia, with a simultaneous measure of cortical and 
trabecular vBMD and a deeper representation of bone 
microarchitecture, thus performing the so-called virtual 
biopsy. A micro-FEA for peripheral bones might be thus 
derived from HR-pQCT scans. A cross-section of the distal 
radius or tibia is scanned at a resolution sufficiently high to 
resolve the trabecular microstructure (in the order of 80 μm). 
Based on these images, micro-FE models are generated and 
a mechanical test is simulated to derive the stiffness of the 
scanned region and to estimate the strength of the whole 
bone. In validation studies, micro-FEA showed its ability 
to predict bone failure load better than any density-based 
parameter, but this improved strength prediction did not 
result in a better separation of subjects with and without 
distal radius fractures in retrospective studies, probably due 
to the reduced reproducibility, and consequently reduced 
specificity and sensitivity, in population retrospective stud-
ies with respect to validation studies performed on cadav-
ers [57]. Currently, several HR-pQCT devices are available 
worldwide [58, 59] and their use is mainly reserved for 
research purposes [60, 61], although there is potential to 
use this technique in the clinical diagnosis and management 
of osteoporosis irrespectiwhether its ability in fracture pre-
diction will be fully demonstrated [59, 61].
Magnetic resonance imaging
In magnetic resonance imaging (MRI), and high-resolution 
MRI as well, the hydrogen atoms in water molecules are 
exploited to obtain a contrast between marrow signal (hyper-
intense) and trabecular structure (hypo-intense). With this 
non-ionizing imaging modality, structural trabecular param-
eters (i.e., trabecular number, thickness, connectivity, anisot-
ropy and shape) might be obtained and FEA can be applied 
similarly to the case of QCT [62]. However, some important 
limitations such as high costs, long scan time, motion arte-
facts and partial volume effects (in case of insufficient image 
resolution that results in reduced contrast between adjacent 
tissues and blurring effects) make this imaging technique 
scarcely employed and investigated in osteoporosis diagno-
sis [63]. Furthermore, to the best of our knowledge, no sig-
nificant longitudinal studies have been conducted to assess 
fracture risk prediction through MRI.
Quantitative ultrasound
Quantitative ultrasound (QUS) devices measure bone prop-
erties using differential reflections and attenuation of pulsed 
ultrasound waves. According to the ISCD Official Positions, 
the only validated skeletal site for the clinical use of QUS in 
osteoporosis management is the heel, which, in conjunction 
with clinical risk factors, can be used in patients aged over 
65 in order to identify low-risk populations [64, 65]. The 
most common parameters of interest for this non-ionizing 
technique are those derived from the combination of the 
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speed of sound (SOS) and the broadband ultrasound attenu-
ation (BUA), like the stiffness index (SI) and the quantitative 
ultrasound index (QUI). SOS, which relies on the accurate 
measurement of the time employed by a sound wave to pass 
through the heel, is directly proportional to the BMD. Anal-
ogously, BUA, which measures the reduction in intensity at 
different frequencies of a broadband ultrasound pulse sent 
through the bone, shows a greater attenuation of the higher 
frequencies in strong bones than in weak bones [66]. The 
SI, for instance, was empirically derived as the sum of the 
normalized BUA and SOS values, with a comparable con-
tribution from the two factors [67].
Population studies have shown the capabilities of heel 
QUS to predict osteoporotic fractures, especially for hip, 
with similar sensitivity but lower specificity than DXA 
in discriminating fractured from non-fractured subjects 
[68–71]. A meta-analysis on 14 prospective studies showed 
that the estimated relative fracture risk ranged between 
1.23 and 1.94 for each SD decrease in QUS measurements 
depending on the measured QUS parameter and the type 
of fracture, suggesting that heel QUS might be used as an 
alternative to DXA in the assessment of non-vertebral frac-
ture risk [72]. However, it has been also reported that QUS 
predictive value wanes with time, being for instance more 
reliable at 1 year after baseline measurement than at 5 years 
[73].
The main advantages of QUS with respect to DXA are 
lower cost, smaller space required, portability and absence 
of ionizing radiation. However, QUS approaches are appli-
cable only to peripheral skeletal sites (calcaneus, tibia, pha-
langes, radius), and their diagnostic performances are typi-
cally inferior to the corresponding DXA ones. Moreover, the 
availability of several QUS devices that differ substantially 
from each other in terms of measured parameters has limited 
their acceptance. Furthermore, QUS results are also depend-
ent on operator, anatomical location, and relative position-
ing of bone and ultrasound transducer: these drawbacks cur-
rently limit the employment of QUS as a clinical diagnostic 
tool, except for screening purposes [47, 64].
Role of bone strength in the assessment 
of fracture risk: state of the art
Areal BMD
Modelling bone strength might have implications for the 
understanding of osteoporosis mechanism, the assessment 
of fracture risk and the prediction, and monitoring of drug 
treatments. As expressed above, the main clinically available 
indicator to predict fracture risk is areal BMD estimated by 
DXA imaging.
In a study by Kopperdahl et al. [48], derived from the 
AGES-Reykjavik case-control cohort, the large majority of 
fracture events seems to occur when femoral neck T-score 
of areal BMD was below about − 1.5. However, the abil-
ity of this parameter to predict hip fractures significantly 
improved only if combined with femoral strength estima-
tion for a net reclassification improvement of 33%. Bone 
strength estimated from QCT-derived FEA was signifi-
cantly correlated with fracture risk, when adjusted for age 
and sex, independently from baseline BMD, indicating that 
a reduced bone strength might be a predictive factor for 
high risk of osteoporotic fracture.
The predictive ability over a long period of areal BMD 
was evaluated in the Study of Osteoporotic Fractures 
(SOF) [74], which assessed BMD and risk factors in 
almost 8000 women between 1988 and 1990, with a clini-
cal follow-up for fractures lasting for 25 and 20 years for 
hip and any non-vertebral fracture, respectively. Although 
BMD alone might be predictive of fracture risk, the over-
all prediction would be improved by taking into account 
other risk factors and other bone quality descriptors more 
closely related to bone strength.
The sensitivity of areal BMD to treatment changes was 
assessed in studies evaluating drug treatments, such as 
the FREEDOM study (Denosumab versus placebo) [75] 
and the HORIZON study (Zoledronic versus placebo) 
[76], showing that an increase in total hip BMD after 
3 years of treatment was correlated with a decrease in 
risk of non-vertebral fracture and, interestingly, the risk 
of fracture showed similar relationships (slopes) with per 
cent change in total hip BMD for both drug and placebo 
groups (Fig. 3, [75]). Moreover, a meta-regression of 38 
placebo-controlled trials with follow-up ranging from 1 to 
8 years showed that increments of 2–6% in total hip BMD 
were significantly associated with a 28–66% reduction in 
vertebral fractures, as well as with a 16–40% reduction 
in hip fractures, but not with reductions in non-vertebral 
fractures [77]. In general, in the osteoporosis treatment, 
the time-interval of repeated DXA-BMD measurements 
must be long enough to discern real BMD increments from 
precision error of repeated measurements (in the order of 
1–2%) [78], with reasonable interval not less than 2 years.
In summary, areal BMD estimated by DXA imaging 
showed reasonable diagnostic performances being dis-
criminative, predictive and sensitive to treatment changes. 
However, it is widely accepted that a deeper analysis of 
bone biomechanics is needed to increase the accuracy of 
fracture risk prediction by taking into account the actual 
bone strength [3, 17, 79, 80].
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High‑resolution peripheral QCT (HR‑pQCT)
The main clinical issue associated with the use of BMD 
alone is the twilight zone of osteopenic patients, where the 
majority of fractures occurs, suggesting that the standard 
classification may overlook some important biomechani-
cal characteristics that could improve the assessment of 
fracture risk [81]. For instance, the discriminative value 
of parameters derived from HR-pQCT at the distal radius 
(i.e., total and trabecular density and heterogeneity of tra-
becular network) was assessed in a setting of osteopenic 
postmenopausal women (PMW), with and without frac-
tures, in which BMD of the lumbar spine and femoral neck 
did not significantly differ [82]. Statistically significant dif-
ferences were found between fractured and non-fractured 
subjects, with the former having − 10% in total density, 
− 12.3% in trabecular density, and +25.6% in heterogene-
ity of trabecular network [82]. This paper, on the one hand, 
underlined the importance of the description of trabecular 
microarchitecture of peripheral sites for the enhancement 
of the prediction of fracture risk in osteopenic patients, 
but, on the other hand, given the preliminary nature of 
the study and the small number of enrolled patients, it 
also emphasized the need of additional studies to better 
understand the actual usefulness of the mentioned bone 
microarchitecture parameters. A recent study by the Bone 
Microarchitecture International Consortium (BoMIC) 
[83], including 8 large cohorts of patients for a total of 
7254 individuals, investigated the association between 
indices derived from HR-pQCT and fracture risk. During 
an average follow-up of 4.6 years, 86% of incident frac-
tures were registered in patients with femoral neck BMD 
in the osteopenic or normal range, but in whom deficits 
in bone microstructure were found with HR-pQCT. The 
results indicate that trabecular and cortical bone density 
and microstructure, as well as estimated failure load meas-
ured at the peripheral skeleton, predicted incident fractures 
independently of femoral neck BMD and  FRAX®.
Moreover, a large multimodal investigation was per-
formed by Biver et al. [60] in order to assess the contribu-
tion of bone phenotype parameters to the prediction of 
low-trauma fractures in PMW: peripheral trabecular and 
cortical volumetric BMD and microstructure, as well as 
the estimated bone strength by HR-pQCT, showed high 
prediction rate independently of femoral neck BMD, 
 FRAX®, and TBS. As BMD assessed by DXA at the ultra-
distal radius [84] showed very good performance for frac-
ture prediction, the authors suggested that measuring ultra-
distal radius BMD in addition to femoral neck BMD could 
be useful to refine fracture prediction for PMW in this 
age range, especially when bone microstructure cannot be 
specifically assessed due to the limited clinical availabil-
ity of HR-QCT [57–59]. Similarly, a cross-sectional case-
control study found that bone microstructure and strength 
assessment were able to discriminate patients on long-term 
glucocorticoids with vertebral fracture independently of 
BMD: noteworthy, with a reduction in total volumetric 
BMD and cortical thickness at the distal tibia, it was able 
to identify patients at high risk of vertebral fractures in the 
subgroup considered to have low fracture risk as assessed 
by DXA or  FRAX® [85].
The main difficulty in the full assessment of bone strength 
is due to the numerous bone components involved in its defi-
nition. The introduction of advanced tools in clinical prac-
tice is needed in order to collect additional information for 
the modelling of bone strength and fracture risk.
FEA derived from QCT
Several attempts have been performed by FEA derived from 
QCT [86], sometimes including bone anisotropy informa-
tion [87], in order to model bone strength and to assess a 
personalized biomechanical fracture threshold as the ratio 
of external forces applied to the bone and the FE-computed 
bone strength [81]. Micro-FEA derived from HR-pQCT 
was also used in the prospective STRAMBO study, which 
enrolled 825 men that were followed for 8 years, showing 
that the distal radius trabecular number was the parameter 
most strongly associated with fracture risk [88].
Fig. 3  Association between incidence of non-vertebral fracture 
and total hip BMD percent change from baseline at 36  months in 
Denosumab and placebo cohorts. The risk of non-vertebral fracture 
decreased with increasing per cent change in total hip BMD with 
similar relationships (slopes) for both treatment groups. The density 
curves at the bottom represent the distributions of total hip BMD 
change at 36 months for each treatment group [75]
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Microindentation
The recently developed in vivo impact microindentation 
may have a role in the explanation of fracture propensity 
in case of poor bone quality associated with normal BMD, 
such as type 2 diabetes, atypical femoral fractures, stress 
fractures, glucocorticoid treatment and HIV infection [89, 
90]. For instance, in a study by Rozental et al. [91], lower 
bone strength index measured by impact microindentation at 
the anterior surface of the mid-tibia diaphysis in PMW was 
associated with distal radius and hip fractures and, if con-
firmed by prospective trials, might be integrated in models 
for the identification of women at risk of fragility fractures.
DXA‑based 3D modelling
The most promising future approach could be the integra-
tion of the available technologies, such as DXA-based 3D 
modelling, as shown in a retrospective open-label study aim-
ing to assess the effects of treatments on average changes in 
volumetric BMD and trabecular architecture over 24 months 
using DXA-based 3D modelling [92]. Nevertheless, the 
request for a long time to carry out the FEA hampers its use 
in the clinical practice, which will perhaps have to wait for 
the improvement of the underlying technology and mathe-
matical-physical processes.
Currently unmet clinical needs
Despite the mentioned specific added values of some 
imaging methods alternative to DXA, the main routinely 
employed parameter to estimate bone strength and to predict 
fracture risk is still represented by DXA-measured BMD.
In fact, currently there is not a widely accessible and cost-
effective tool capable of significantly improving fracture risk 
estimation in individuals with osteopenic or normal BMD, 
which account for about 50% of fragility fractures [93].
Typically, the described approaches increase the dura-
tion of the diagnostic procedure and ionizing radiation dose 
without a clear improvement of the clinical outcome. For 
instance, a very recent study [94] has evaluated the per-
formance of QCT-based FEA as a predictor of hip fracture 
risk, documenting that, compared to the traditional DXA, 
it would imply a 15% increment in the total costs and an 
over 2000 times higher radiation dose, while reducing the 
fractured patients by less than 5%. This is also coupled with 
the important accessibility issues that are common to all 
the QCT-based techniques, which require all the strictest 
precautions typical of X-ray-bearing techniques, including 
also HR-pQCT, the use of which is further hindered by their 
very limited availability in clinical contexts [57–59].
However, although the cost-effectiveness of osteoporosis 
prevention through early diagnosis has been demonstrated 
[95], the identification of the most cost-effective imaging 
technique through thorough economic analyses (including 
different fracture states, country-specific aspects, etc.) is still 
debated in literature [21, 96] and the definition of a specific 
cost-effectiveness model is beyond the scope of this paper.
Anyway, there is a series of clinical needs that are not 
effectively satisfied because of the previously mentioned 
limitations of the currently employed techniques and 
would require the introduction of reliable methods for bone 
strength evaluation and fracture risk estimation. The most 
urgent of these unmet needs include the following: osteopo-
rosis diagnosis in patient categories for which X-ray exami-
nations are not feasible (e.g., paediatric subjects, pregnant 
and breastfeeding women, etc.); under-diagnosis and late 
diagnosis; effective bone quality assessment integrated with 
a reliable fracture risk prediction available in clinical rou-
tine; short-term follow-up of patients under treatment, since 
the present techniques require at least 1 year between two 
measurements.
Radiofrequency echographic multi 
spectrometry (REMS)
Basic principles
REMS technology is a non-ionizing axial approach for oste-
oporosis diagnosis. The operating principle is based on the 
analysis of native raw unfiltered ultrasound signals, the so-
called radiofrequency (RF) ultrasound signals, acquired dur-
ing an echographic scan of lumbar vertebrae and/or femoral 
neck. The analysis of native unfiltered ultrasound signals 
allows to retain the maximum information about the char-
acteristics of the investigated tissues, which are normally 
filtered out during the conventional process of B-mode 
image reconstruction. The bone health status is assessed 
through the comparison of the analysed signal spectra with 
previously derived reference spectral models for the consid-
ered pathological and normal conditions [97, 98]. The large 
amount of collected data related to internal bone structure 
provides both quantity- and quality-related information, 
being thus theoretically suitable for the estimation of bone 
strength and the prediction of fracture risk.
In more detail, in a REMS investigation, the probe is 
placed on the abdomen or on the hip in order to visualize 
of the target bone interface and the operator has to set the 
appropriate values of scan depth and transducer focus. Sub-
sequently, the software detects the sought bone interfaces in 
the sequence of acquired frames and identifies the regions 
of interest (ROIs) for the diagnostic evaluation (Fig. 4). One 
key-feature lies in the exploitation of B-mode images for 
the identification of target bone interfaces and related ROIs, 
combined with the diagnostic analyses performed on the 
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RF data. REMS analysis is then characterised by the paral-
lel processing of the unfiltered signals of several scan lines 
(Fig. 5).
The analysis of single scan line spectra allows the auto-
matic exclusion of signals corresponding to artefacts, such 
as calcifications or osteophytes, thanks to the identification 
of unexpected spectral features.
The selected measured data are finally synthetized in 
a patient-specific spectrum of the considered bone target, 
which undergoes an advanced comparison with gender-, 
age-, site- and BMI-matched reference spectral models 
extracted from a dedicated database (Fig. 6).
Actually, the spectral modifications introduced by the 
physical properties of the bone structure that has backscat-
tered the ultrasound signals are identified by the compari-
son procedure, resulting in a BMD estimation and in the 
consequent diagnostic classification as healthy, osteopenic 
or osteoporotic. The adopted approach is based on the cal-
culation of the Osteoporosis Score, which corresponds to 
the percentage of analysed spectra that were classified as 
“osteoporotic” through the dedicated spectral analyses [97, 
98]. Linear equations are then employed to transform Osteo-
porosis Score into BMD values.
REMS approach has the potential to calculate also param-
eters different from BMD, derived from bone quality indi-
cators and further related to bone strength. Among these, 
Fragility Score (FS) has been developed as an independ-
ent indicator of bone quality that provides an estimation of 
fracture risk independently of BMD. It is a dimensionless 
number in the range 0–100 obtained from the comparison 
between the patient-specific spectrum and reference spectral 
models obtained from patients with and without osteoporotic 
Fig. 4  Software-guided REMS acquisition on femoral neck. Before 
starting the acquisition, the operator sets transducer focus and scan 
depth in order to visualize the target bone interphase in the central 
part of the echographic field of view, immediately below the focus 
position. The software automatically detects the bone interface and 
identifies the region of interest (ROI)
Fig. 5  REMS analysis is charac-
terised by the parallel process-
ing of the native raw unfiltered 
signals of several scan lines, 
deriving one spectrum from 
each scan line (sample spectra 
are shown on the right)
Fig. 6  Patient-specific spectra undergo advanced comparisons with 
age-, sex-, BMI- and site-matched spectral models of pathologic and 
healthy conditions
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fractures. Recent preliminary studies have shown that FS 
has a good accuracy in the discrimination between fractured 
and non-fractured subjects, and also that FS is significantly 
correlated with the fracture risk calculated by  FRAX® when 
the latter included also the results of the femoral neck den-
sitometry [99–101].
Ongoing developments of REMS are addressed to the 
investigation of other musculoskeletal tissues, such as mus-
cles and cartilage, in order to monitor the onset and evo-
lution of diseases like sarcopenia and arthrosis by early 
detecting the corresponding tissue deteriorations through 
dedicated REMS parameters.
Clinical validation studies
The application of REMS technology for osteoporosis diag-
nosis has been clinically validated through an observational 
multicentre clinical trial involving 7 Italian centres that 
enrolled over 1900 PMW [102]. The aim of the study was 
to assess the precision and diagnostic accuracy of REMS in 
comparison with the clinical gold standard reference, repre-
sented by DXA. All DXA acquisitions were double-checked 
to avoid possible errors as identified by Messina et al. [103]. 
Similarly, a quality control was performed on all the REMS 
reports in order to verify the correct selection of scan depth 
and transducer focus. The analysis of the temporal distri-
bution of the errors indicated the possibility of improving 
the clinical practicability of REMS through a more rigorous 
training of the operators, aimed at reducing the time span of 
the learning curves and the related initial error rates. After 
the cross-check, 1195 spinal and 1373 femoral comparable 
cases were analysed.
The REMS intra-operator precision, expressed as root-
mean-square coefficient of variation (RMS-CV) was 0.38% 
(95% confidence interval: 0.28–0.48%) for lumbar spine and 
0.32% (0.24–0.40%) for femoral neck. The corresponding 
least significant change for the 95% confidence level, calcu-
lated via the ISCD precision calculator (available at http://
www.iscd.org/resou rces/calcu lator s/), was 1.05% for lumbar 
spine and 0.88% for femoral neck. The inter-operator repeat-
ability was 0.54% for spine and 0.48% for femoral neck.
Afterwards, diagnostic accuracy of REMS was assessed 
by determining the concordance of REMS and DXA in 
the discrimination between osteoporotic, osteopenic and 
healthy patients through the calculation of the correspond-
ing Cohen’s kappa (k), obtaining k = 0.82 for lumbar spine 
and k = 0.79 for femoral neck.
Sensitivity of REMS in discriminating osteoporotic sub-
jects from non-osteoporotic ones turned out to be 91.7% 
for spine and 91.5% for femur, while specificity was 92.0% 
and 91.8%, respectively. Furthermore, the degree of cor-
relation between DXA and REMS T-score values resulted 
to be r = 0.94 for lumbar spine and r = 0.93 for femoral neck 
(p < 0.001 for both).
Moreover, the agreement between BMD values obtained 
by DXA and REMS was calculated through the Bland–Alt-
man method [104]: the average difference (expressed as 
bias ± 2 SDs) was − 0.004 ± 0.088 g/cm2 for lumbar spine 
and − 0.006 ± 0.076 g/cm2 for femoral neck. The standard 
error of the estimate (SEE) resulted equal to 0.044 g/cm2 
(5.3%) for lumbar spine and 0.038 g/cm2 (5.8%) for femoral 
neck.
The results obtained from the referred multicentre clinical 
study showed that REMS technology has a high sensitivity 
and specificity in osteoporotic patient identification, with 
a significant diagnostic agreement with the gold standard 
DXA in the classification of patients as healthy, osteopenic 
or osteoporotic (total diagnostic concordance was 88.8% for 
lumbar spine and 88.2% for femoral neck). Both intra- and 
inter-operator variability associated with REMS investiga-
tions were better than the corresponding values typically 
reported in literature for the employed comparative gold 
standard DXA [105, 106].
Thanks to its radiation-free approach, REMS might be 
applied for population mass investigations or prevention pro-
grams, early diagnosis in clinical practice and therapeutic 
short-term follow-up.
In the meantime, in October 2018 the first device imple-
menting the REMS approach has received the clearance of 
the U.S.A. Food and Drug Administration (FDA) for the 
measurement of the diagnostic parameters BMD, T-score 
and Z-score, and for monitoring bone changes in the clini-
cal routine.
Further studies and clinical perspectives
An International Multicentre Clinical Trial, called “Echo-
Bone” and focused on an extended study of the REMS 
approach for osteoporosis diagnosis in a wide European 
clinical context through a head-to-head trial with DXA, is 
currently ongoing in five reference centres for osteoporosis 
management. At an interim analysis on 595 patients enrolled 
in Barcelona (Spain) [107], preliminary data confirm the 
recently published results [102].
Then, another recently completed longitudinal study 
[108] has quantified the predictive value of REMS T-score in 
identifying patients at risk for osteoporotic fractures by per-
forming a follow-up of up to 5 years for the possible occur-
rence of fragility fractures in a population of 1370 women 
who had undergone baseline spinal REMS and DXA scans. 
After the follow-up period, all the subjects were divided 
into two Groups: Group A (with incident fractures) and 
Group B (without incident fractures). As expected, signifi-
cant differences between the two groups were found in both 
REMS T-score (− 2.68 ± 1.28 in Group A vs − 2.03 ± 1.23 
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in Group B, p < 0.001) and DXA T-score (− 2.52 ± 1.20 
in Group A vs − 2.08 ± 1.17 in Group B, p < 0.001). The 
employment of the typical threshold of T-score ≤ − 2.5 as a 
cut-off value for both the techniques produced the follow-
ing results in the identification of Group A patients by the 
two techniques: sensitivity = 65% and specificity = 57% for 
REMS (OR = 2.6); sensitivity = 57% and specificity = 57% 
for DXA (OR = 1.7). This performance of REMS T-score 
in the identification of patients at high risk for osteoporotic 
fractures will have to be further verified on a wider popula-
tion through the outcome of a similar study that is currently 
ongoing in six clinical centres.
In general, the available data suggest that REMS technol-
ogy might have a beneficial impact on current diagnostic 
protocols and subsequent patient management in the clinical 
routine. Further clinical scenarios are envisaged for addi-
tional REMS applications, including in particular fracture 
risk assessment in paediatric patients and pregnant women, 
and also in patients at risk of secondary osteoporosis (e.g., 
diabetic, nephropathic, oncological patients).
REMS adoption in the clinical routine is expected to 
increase in the near future because of the mentioned evi-
dences and advantages, and also because the technology 
is currently undergoing the evaluation procedures to be 
included in the relevant international guidelines. Notewor-
thy, this technology does not require radiological protec-
tion, which might have been a problem for the reception 
in primary care in some countries. Finally, the portability 
facilitates the employment on hospitalized fractured patients 
not-transferrable to the densitometry units and on patient 
follow-up at home.
Conclusions
The impact of osteoporosis and the resulting bone fracture 
on both patient’s life and healthcare systems is constantly 
increasing: means for early diagnosis and monitoring of this 
disease are urgently needed in order to prevent and reduce 
the occurrence of fractures. BMD measurement based on 
DXA remains the current gold standard for osteoporosis 
classification, as defined by WHO. However, the above-
mentioned clinical situation and the reported limitations of 
this technique boosted the scientific research to identify reli-
able and accurate alternative approaches for bone strength 
estimation and identification of individuals at high risk of 
fracture. Those efforts are leading to a deeper understand-
ing of intrinsic bone characteristics, related not only to bone 
quantity but also to bone quality, which might contribute to 
improve the accuracy of bone strength measurement and 
fracture risk assessment.
In this context, REMS represents the first clinically avail-
able method for direct non-ionizing measurement of lumbar 
and femoral BMD. Available scientific evidences describe 
REMS-estimated BMD as an accurate diagnostic parameter, 
which resulted also a predictor of incident clinical fracture 
risk in a representative sample of female subjects. Moreover, 
REMS has shown a further potential in the assessment of 
skeletal fragility based on bone structure quality through 
the Fragility Score parameter, which is independent from 
the densitometric evaluation.
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